Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 12,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: combined therapy treatment Clear all

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Wilmington, Delaware • Tampa, Florida + 4 more

Conditions: Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions: MESENDO; Biological
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Smoking Cessation
Interventions: Empowerment activity-enhanced tobacco cessation assistance; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions: CX-2009, CX-072; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, TAK-875, Sitagliptin, TAK-875 and Sitagliptin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 80
States / cities: Birmingham, Alabama • Brimingham, Alabama • Chandler, Arizona + 77 more

Conditions: Pancreatic Cancer
Interventions: Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 4 more

Conditions: Solid Tumor, Adult
Interventions: GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®; Biological · Drug
Lead sponsor: Nouscom SRL; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 9 more

Conditions: Glioblastoma, Adult
Interventions: Multiple dose of EO2401; Biological
Lead sponsor: Enterome; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic Pain
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Ventura, California + 9 more

Conditions: Brain Concussion, Mild Traumatic Brain Injury
Interventions: Physical Therapy; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 13 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orland Park, Illinois • Niagara Falls, New York

Conditions: Relapsed Sarcomas
Interventions: Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil); Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: Insulin detemir, Glargine, NPH; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Solid Tumor
Interventions: 68Ga-FAP-2286, 177Lu-FAP-2286; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 16 more

Conditions: Alcohol Use Disorder
Interventions: CI-581a, CI-581b, MBRP, MET; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 23
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 15 more

Conditions: Weight Loss, Weight Prejudice
Interventions: Internalized Weight Bias Intervention; Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Multiple Myeloma, Neoplasms
Interventions: cetuximab, vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 11
States / cities: Tucson, Arizona • Aurora, Colorado • Boston, Massachusetts + 6 more

Conditions: Diabetic Macular Edema
Interventions: Dexamethasone, Sham injection, Laser Photocoagulation; Drug · Procedure
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Artesia, California

Conditions: Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Elacestrant, DC1 native/mutated ESR1; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy; Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more

Conditions: Esophageal Cancer
Interventions: Erlotinib, 5-fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anaplastic Thyroid Cancer
Interventions: Cemiplimab, Zanzalintinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Alzheimer's Disease
Interventions: Exercise Training, Cognitive Training, Flexibility Training, Educational Sessions; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 60 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

Empowering LGBTQ+ Tobacco Cessation Pilot

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

The Role of Mechanical Diagnosis and Therapy in the Management of Concussion

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Virtual Third-Wave Intervention for Internalized Weight Bias Combined With a Weight Loss Program

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults